<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B863A1B5-18E2-4DCE-8A84-7DD2C73D6597"><gtr:id>B863A1B5-18E2-4DCE-8A84-7DD2C73D6597</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Blackbourn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400408"><gtr:id>8F7756C8-0BFC-4F41-9184-A99BB49773E6</gtr:id><gtr:title>Functional studies of the KSHV vIRF-2 protein</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400408</gtr:grantReference><gtr:abstractText>Some of the most common herpesviruses are household names since they are the causes of many familiar human diseases, including chicken pox, shingles and oral and genital ulcers. Epstein-Barr virus (EBV) which causes infectious mononucleosis (or student?s kissing disease) is another herpesvirus that is a cofactor in the development of certain cancers of white blood cells (lymphomas) and of the oral-nasal cavity. Kaposi?s sarcoma-associated herpesvirus (KSHV), a relative of EBV, is the probable cause of Kaposi?s sarcoma (KS) and a rare form of lymphoma, especially in individuals infected with HIV, which causes AIDS. KS is the most common malignancy affecting AIDS patients. However, KS also affects others, including organ transplant recipients. The identification of KSHV as a new human pathogen offers exciting opportunities to investigate how it and related herpesviruses cause disease. Discoveries concerning this virus could be extended to other herpesviruses to contribute overall to our understanding of herpesvirus biology and help in devising methods to develop medicines against them.
This proposal aims to provide a deeper understanding of how KSHV interacts with an important component of our bodies defence system: the innate interferon immune response . Our preliminary studies indicate that one component of KSHV is a protein called vIRF-2 that we have begun to characterise. This viral protein inhibits the innate interferon immune response, presumably because the virus needs to evade this defence system. If we can understand how the viral protein achieves this inhibition, we will have a better understanding of the mechanics of the response, and perhaps how other viruses avoid it. Eventually, our work could then help in the development of medicines and vaccines to prevent viruses and other foreign organisms overcoming this response.
DJB is a ?GU Teacher-Scientist? and a Science Ambassador for the national SETPOINT programme. He interacts regularly with Lenzie Academy High School, giving talks on current virology topics (AIDS, SARS, Avian flu, etc) and his research. He judges in the annual Lenzie Academy science competition. For National Science week, 2004, at GU, DJB spoke on ?Introducing Virology?.</gtr:abstractText><gtr:technicalSummary>Interferons (IFN) induce an antiviral state in virus-infected cells through signalling that can involve interferon regulatory factors (IRF). Kaposi?s sarcoma-associated herpesvirus (KSHV) is the aetiologic agent of KS, which is the most common malignancy affecting AIDS patients and the most frequently occurring tumour in Africa. The virus is unique among viruses that infect humans in that it encodes a family of four homologues of the cellular IRFs that are referred to as viral (v) IRFs. The only other virus to encode vIRFs is the KSHV-related rhesus rhadinovirus. We have characterised the transcription profile of the KSHV vIRFs and showed that one of them, vIRF-2 protein, is encoded by a spliced gene. Our preliminary data show that vIRF-2 protein inhibits the type I interferon immune response. In particular, we have shown that vIRF-2 protein inhibits IRF-3 transcriptional activation and signalling by IFN-a and the new IFN-l family members. The present proposal focuses on understanding how vIRF-2 protein achieves this inhibition. We hypothesise that vIRF-2 protein interacts with cellular partner proteins important in IFN signalling. Identifying these partners will provide a detailed understanding of how vIRF-2 protein functions, presumably to facilitate disseminated infection of the host, and could further our understanding of the mechanisms regulating the interferon type I signalling cascade.</gtr:technicalSummary><gtr:fund><gtr:end>2009-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>234027</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>CR UK Relay for Life, Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>64BDA017-E0F9-48EA-8381-2D9B01E3166A</gtr:id><gtr:impact>~30 minute talk on my research

~&amp;pound;20,000 raised for CR UK at this Relay for Life.</gtr:impact><gtr:outcomeId>59994256C2E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Society for British Gas Industries, Birmingham. Formal presentation.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>EFF65784-CE87-42D7-ACA1-3C1399BC65F1</gtr:id><gtr:impact>~10 minute talk at CR UK-fund raising dinner

&amp;gt;&amp;pound;7000 raised for research.</gtr:impact><gtr:outcomeId>C8A7A424761</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CR UK Regional Manager's meeting.  Kettering</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F2DA0839-5286-4E66-999C-9E08E9C0BCD8</gtr:id><gtr:impact>~40 minute talk on my research

Motivated CR UK employees</gtr:impact><gtr:outcomeId>E675BF2F61C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Immune modulation strategies of Kaposi's sarcoma-associated herpesvirus (KSHV) persistence</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>30BE8136-9E97-4D40-99DC-79C74F2F9844</gtr:id><gtr:impact>~40 minute lecture as Keynote Speaker, European Clinical Virology Meeting. Birmingham, UK

Unsure</gtr:impact><gtr:outcomeId>197CF7DCF77</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>170000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Functional studies of the KSHV complement control protein, KCP</gtr:description><gtr:end>2009-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>7972AD6A-3080-4C1D-ADFD-C9F4E694BDBC</gtr:id><gtr:outcomeId>ipnTF9n4i9F0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>411462</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Inhibition of antigen-specific T cells by KSHV vOX2 and its cellular counterpart, CD200</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D7AD735B-F829-41B6-84BC-88281B6CF11A</gtr:id><gtr:outcomeId>jgJhxbv2nuB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>264694</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Understanding the functional consequences of endothelial cell infection by KSHV</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>EFE898DB-E370-4A20-9D29-37B01FCEF3BF</gtr:id><gtr:outcomeId>GTTM153w1Ww0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Expression plasmids</gtr:description><gtr:id>6729CB6B-D37C-4231-8D99-45F8A15CAD5D</gtr:id><gtr:impact>Furthering the fields of immunology and immune evasion by viruses</gtr:impact><gtr:outcomeId>7156BEA2FAD</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>vIRF-2</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>01649A41-1F6E-4996-B1EA-DACDD8B6B196</gtr:id><gtr:title>Structural properties of a viral orthologue of cellular CD200 protein: KSHV vOX2.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaa573449a408ca1e73096e142d8b78e"><gtr:id>aaa573449a408ca1e73096e142d8b78e</gtr:id><gtr:otherNames>Amini AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>doi_55f9849849b58f28</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>059E354D-921E-4BBB-A1AE-5ACDD4810C4F</gtr:id><gtr:title>The viral interferon regulatory factors of kaposi's sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7203f1a9027410dd3834549c2cfe7fc3"><gtr:id>7203f1a9027410dd3834549c2cfe7fc3</gtr:id><gtr:otherNames>Jacobs SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13489_29_23115281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8810824F-2058-4F36-A1B6-51D21C3688DF</gtr:id><gtr:title>Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor-2 inhibits type 1 interferon signalling by targeting interferon-stimulated gene factor-3.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0edf02c88c177100685290115f209db"><gtr:id>c0edf02c88c177100685290115f209db</gtr:id><gtr:otherNames>Mutocheluh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>doi_55f98398380e3edc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5F245EF-B7F4-4AA4-B630-FD8FDCFCCC88</gtr:id><gtr:title>Identification and functional characterization of a spliced rhesus rhadinovirus gene with homology to the K15 gene of Kaposi's sarcoma-associated herpesvirus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>C74A46907E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DFC1927-C21E-4C08-9FA6-DC517419610D</gtr:id><gtr:title>Kaposi's sarcoma-associated herpesvirus immune modulation: an overview.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e217ac1b95630daedd738ce2cc6f1abf"><gtr:id>e217ac1b95630daedd738ce2cc6f1abf</gtr:id><gtr:otherNames>Rezaee SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>6F2FA389995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C1192A6-3AD5-43D5-8C98-7DB7CBBDD491</gtr:id><gtr:title>Risk factors in the development of Kaposi's sarcoma.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1281866d4f1398112bc99ea43d4ae32"><gtr:id>b1281866d4f1398112bc99ea43d4ae32</gtr:id><gtr:otherNames>Colman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>22FEE9AC292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C8F2152-D9BA-49EC-B568-E489E2C1A7D7</gtr:id><gtr:title>Innate barriers to viral infection.</gtr:title><gtr:parentPublicationTitle>Future microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bf3f1f1c3ac45facc93b885f05ffa9b"><gtr:id>1bf3f1f1c3ac45facc93b885f05ffa9b</gtr:id><gtr:otherNames>Damania B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-0913</gtr:issn><gtr:outcomeId>pm_13489_29_22827304</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1F95D91-0430-4CAC-ACFE-E24F7BF925FF</gtr:id><gtr:title>Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bb19d77ca779371ac372d3b6ec47e3e"><gtr:id>0bb19d77ca779371ac372d3b6ec47e3e</gtr:id><gtr:otherNames>Okroj M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>52696E47929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8184AF40-9DF9-4187-B164-A986D94ECCE8</gtr:id><gtr:title>Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81ca046a3190a60da9634f74bff146ec"><gtr:id>81ca046a3190a60da9634f74bff146ec</gtr:id><gtr:otherNames>Arest? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>3D34F9CCE92</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDFAA79F-E64B-4C60-8F00-56AF3B3D1680</gtr:id><gtr:title>Infection and transmission dynamics of rKSHV.219 in primary endothelial cells.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>pm_540e13be13b184d12</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D89E4F8-E6FB-4E83-BF4E-5AA6E5C20CE8</gtr:id><gtr:title>Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81ca046a3190a60da9634f74bff146ec"><gtr:id>81ca046a3190a60da9634f74bff146ec</gtr:id><gtr:otherNames>Arest? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>DA0A423DA99</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65E8A4C6-77FC-4DF9-9744-390F810FCC7B</gtr:id><gtr:title>Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a244f807ed1d6f0c6d6f79d10a3b867"><gtr:id>6a244f807ed1d6f0c6d6f79d10a3b867</gtr:id><gtr:otherNames>Butler LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13489_29_22532676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24E34CF4-2711-438B-984A-27185308A865</gtr:id><gtr:title>Suppression of antigen-specific T cell responses by the Kaposi's sarcoma-associated herpesvirus viral OX2 protein and its cellular orthologue, CD200.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df47dbc2e09a70b6e4b08fa97fe8bd05"><gtr:id>df47dbc2e09a70b6e4b08fa97fe8bd05</gtr:id><gtr:otherNames>Misstear K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13489_29_22491458</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400408</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>